TALAPRO-1 Patient Summary This trial is for patients with metastatic Castration-Resistant Prostate Cancer with certain mutations in DNA-damage-repair genes and who previously received taxane-based chemotherapy and progressed on enzalutamide or abiraterone. More information and to check your eligibility for this trial:
PHEN Contact: 617-481-4020
Go Back |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |